ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · Real-Time Price · USD
0.5875
-0.0411 (-6.54%)
At close: Apr 1, 2025, 4:00 PM
0.6017
+0.0142 (2.42%)
After-hours: Apr 1, 2025, 5:51 PM EDT

ZyVersa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
7.3611.218.035.585.36
Research & Development
1.783.215.812.126.47
Operating Expenses
9.1414.4213.837.711.83
Operating Income
-9.14-14.42-13.83-7.7-11.83
Interest Expense
-0.27--0.43-0.82-0.52
Interest & Investment Income
-0---
Other Non Operating Income (Expenses)
---0.610.23-0.33
EBT Excluding Unusual Items
-9.41-14.42-14.87-8.3-12.68
Impairment of Goodwill
--11.9---
Other Unusual Items
---0.21-
Pretax Income
-9.41-107.75-14.87-8.08-12.68
Income Tax Expense
0.01-9.46-0.75--
Net Income
-9.41-98.3-14.12-8.08-12.68
Preferred Dividends & Other Adjustments
-7.95---
Net Income to Common
-9.41-106.25-14.12-8.08-12.68
Shares Outstanding (Basic)
102320
Shares Outstanding (Diluted)
102320
Shares Change (YoY)
1038.49%-99.58%849.06%3478.59%-
EPS (Basic)
-8.48-1089.70-0.62-3.35-187.81
EPS (Diluted)
-8.48-1089.70-0.62-3.35-187.81
EBITDA
-9.13-14.41-13.82-7.69-11.82
D&A For EBITDA
0.010.010.010.010.01
EBIT
-9.14-14.42-13.83-7.7-11.83
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q